Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down – Here’s Why

Genmab A/S (OTCMKTS:GNMSF)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $274.75, but opened at $252.70. Genmab A/S shares last traded at $252.70, with a volume of 47 shares traded.

Genmab A/S Stock Down 0.1%

The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01. The stock’s fifty day simple moving average is $298.38 and its two-hundred day simple moving average is $306.60. The company has a market capitalization of $16.44 billion, a price-to-earnings ratio of 17.25 and a beta of 0.92.

Genmab A/S (OTCMKTS:GNMSF) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $0.55 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.10 by ($2.55). Genmab A/S had a return on equity of 17.35% and a net margin of 25.89%.The business had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.05 billion.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.